Analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $71.31 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $61.50 million and the highest is $79.29 million. Alnylam Pharmaceuticals reported sales of $21.03 million during the same quarter last year, which would suggest a positive year over year growth rate of 239.1%. The business is scheduled to issue its next earnings report on Thursday, February 6th.
According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $220.35 million for the current year, with estimates ranging from $209.57 million to $227.35 million. For the next year, analysts anticipate that the business will report sales of $427.53 million, with estimates ranging from $385.45 million to $470.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.17) by $0.25. The business had revenue of $70.06 million during the quarter, compared to analysts’ expectations of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The business’s revenue for the quarter was up 3284.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.56) earnings per share.
Several brokerages have issued reports on ALNY. Stifel Nicolaus set a $116.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 target price for the company. in a report on Wednesday, September 18th. Bank of America began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday. They issued a “buy” rating and a $110.00 target price for the company. Piper Jaffray Companies set a $145.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 10th. Finally, Cowen decreased their target price on shares of Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $111.50.
Shares of Alnylam Pharmaceuticals stock opened at $90.58 on Thursday. The company has a quick ratio of 5.22, a current ratio of 5.38 and a debt-to-equity ratio of 0.17. Alnylam Pharmaceuticals has a 52-week low of $60.27 and a 52-week high of $96.08. The company has a 50-day simple moving average of $84.57 and a two-hundred day simple moving average of $78.09.
In related news, CEO John Maraganore sold 49,456 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $79.45, for a total transaction of $3,929,279.20. Following the completion of the sale, the chief executive officer now directly owns 239,449 shares in the company, valued at $19,024,223.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Barry E. Greene sold 58,913 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total transaction of $5,301,580.87. Following the sale, the president now owns 111,851 shares of the company’s stock, valued at $10,065,471.49. The disclosure for this sale can be found here. 3.60% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Maverick Capital Ltd. grew its position in Alnylam Pharmaceuticals by 31.9% during the second quarter. Maverick Capital Ltd. now owns 4,236,016 shares of the biopharmaceutical company’s stock valued at $307,365,000 after buying an additional 1,025,629 shares during the period. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 7.6% during the second quarter. Vanguard Group Inc. now owns 9,316,686 shares of the biopharmaceutical company’s stock valued at $676,018,000 after buying an additional 657,595 shares during the period. Farallon Capital Management LLC grew its position in Alnylam Pharmaceuticals by 120.0% during the second quarter. Farallon Capital Management LLC now owns 1,100,000 shares of the biopharmaceutical company’s stock valued at $79,816,000 after buying an additional 600,000 shares during the period. Baillie Gifford & Co. grew its position in Alnylam Pharmaceuticals by 9.3% during the second quarter. Baillie Gifford & Co. now owns 6,213,470 shares of the biopharmaceutical company’s stock valued at $450,850,000 after buying an additional 528,966 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $28,946,000. Institutional investors own 93.51% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.